Darbetin IV/SC 25 mcg/0.42 ml is a Product of the Generic Darbepoetin Alfa

Darbetin IV/SC 25 mcg/0.42 ml belongs to the generic category of Darbepoetin Alfa. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Darbetin IV/SC 25 mcg/0.42 ml. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Darbepoetin Alfa and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

Description of Darbetin IV/SC 25 mcg/0.42 ml

Darbetin IV/SC 25 mcg/0.42 ml may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Darbetin IV/SC 25 mcg/0.42 ml is provided below to help users gain a clear understanding of this medicine.

What Is Darbetin IV/SC 25 mcg/0.42 ml Indications and Uses?

Darbetin is indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis. The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

Pharmacology (Source, Chemical and Physical Composition) Of Darbetin IV/SC 25 mcg/0.42 ml

Darbetin IV/SC 25 mcg/0.42 ml (Darbepoetin Alfa) is an erythropoiesis-stimulating protein that is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. It is a 165-amino acid protein that differs from recombinant human erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant human erythropoietin contains 3 chains. The 2 additional N-glycosylation sites result from amino acid substitutions in the erythropoietin peptide backbone.

Drug Interactions of Darbetin IV/SC 25 mcg/0.42 ml

No formal drug interaction studies have been conducted with Darbetin.

Side Effects of Darbetin IV/SC 25 mcg/0.42 ml

Hypertension, stroke, thromboembolic events, convulsions, allergic reactions, rash/erythema and Pure Red Cell Aplasia (PRCA).

Precautions And Warnings for Darbetin IV/SC 25 mcg/0.42 ml

Darbetin should be used with caution in patients with controlled hypertension, seizures, Pure Red Cell Aplasia (PRCA) or suspected allergy to the product.

Use During Pregnancy and Lactation

Pregnancy Category C. It is not known whether Darbetin IV/SC 25 mcg/0.42 ml (Darbepoetin Alfa) is excreted in human milk. Caution should be exercised when Darbepoetin alfa is administered to a nursing woman.

Therapeutic Class

Haematopoietic Agents

Storage Conditions of It

Store at 2°C to 8°C. Do not freeze. Do not shake. Protect from light; store Darbetin in the carton until use. Do not use Darbetin that has been shaken or frozen. Pack Image: Darbetin 25 mcg/0.42 ml Injection Thanks for using MedEx! How would you rate your experience so far?